Tag: drugs

 ABO-101 is an investigational gene editing therapy designed to address the underlying disease biology of PH1 by reducing hepatic oxalate production

OAKVILLE, Ontario, June 25, 2026 (GLOBE NEWSWIRE) -- As Canadians gather with family and friends to celebrate Canada Day, one of the busiest times of the summer on Canadian roads and waterways, MADD Canada is reminding everyone to never drive after consuming alcohol, cannabis, and/or other drugs.

STOCKHOLM, Sweden, June 25, 2026 – AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, today announced the publication in The Lancet of results from its Phase 1b/2a GOAL-HF1 study evaluating AC01, a first-in-class, oral calcium-sensitising contractile agent, in patients with heart failure with reduced ejection fraction (HFrEF). The results showed a favourable safety and tolerability profile, dose-proportional pharmacokinetics with confirmed target engagement. In exploratory efficacy analyses, numerical rapid and sustained improvements in haemodynamics and cardiac structure and function were observed on top of optimised guideline-directed medical therapy (GDMT).

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- RoenRx, a telehealth platform providing medically supervised weight-loss care, today released updated 2026 pricing information for its weight-loss program, detailing membership costs, insurance-supported GLP-1 treatment options, compounded medication pricing, bundled care plans, and subscription terms. The pricing overview is intended to provide prospective patients with greater transparency regarding the potential costs associated with RoenRx's weight-management services and available treatment pathways.